Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Oct

18

Evolving Expectations for Dermatological Conditions

Read More Share:linkedin| twitter| email

Oct

17

UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

Read More Share:linkedin| twitter| email

Oct

17

Steadfast Towards Our Ambition to Create a UCB Rare Disease Portfolio

Read More Share:linkedin| twitter| email

Oct

13

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Read More Share:linkedin| twitter| email

Oct

13

Going Beyond the Medicine: How UCB Is Addressing the Needs of People Living with Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

Oct

12

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

Oct

04

UCB presents late-breaking posters at Child Neurology Society Meeting

Read More Share:linkedin| twitter| email

Oct

02

“Disease modification” in epilepsies: key questions answered

Read More Share:linkedin| twitter| email

Sep

28

Employee Spotlight: Jessie Kim's Journey as a Global Regulatory Fellow

Read More Share:linkedin| twitter| email

Sep

12

Disease Spotlight: Thymidine Kinase 2 Deficiency (TK2d)

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)